Pharma News
mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta
mAbxience announced in February 2024 a pivotal agreement with Biosidus to manufacture Agalsidase Beta. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease.
Biosimilars lawsuits and settlement updates for Regeneron and Alvotech
In January 2024, Regeneron filed a lawsuit against Amgen in the federal court in Los Angeles, alleging Amgen's proposed biosimilar of Regeneron's Eylea (aflibercept) violates patent rights. Additionally, in February 2024, Iceland-based Alvotech announced the anticipated global market entry dates for AVT04, a ustekinumab biosimilar to Stelara, following its settlement with Johnson & Johnson.
The journey of Pectuna pertuzumab follow-on biological in Iran
Pertuzumab is a monoclonal antibody (mAb) that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation. It is a pivotal therapeutic in oncology, targeting the overexpressed HER2 protein, particularly in breast cancer [1].
Sandoz US acquisition of ranibizumab biosimilar from Coherus
On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.
Fiocruz and Pfizer sign agreement for generic of Xeljanz
Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.
Biocon to commercialize biosimilars in 31 European countries
Biocon Biologics has successfully integrated Viatris’ biosimilars business in 31 European countries, it was announced in late November 2023.
Genfar: Eurofarma's new generic brand in Latin America
Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.
Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product
Ocrelizumab is a therapeutic monoclonal antibody (mAb) that represents a different scientific approach to treating multiple sclerosis (MS). It is a humanized anti-CD20 mAb that targets CD20 marker on B lymphocytes, a typo of immune cell that plays a key role in the disease and serves as an immunosuppressive drug. Ocrelizumab binds selectively to CD20, which is expressed on the membrane of B cells. When ocrelizumab binds to CD20 on B cells, these cells are eliminated by antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.
Insulin biosimilars: new CRL for Biocon, new deal for Meitheal/Tonghua Dongbao
In a dynamic landscape of pharmaceutical developments, Biocon Biologics (Biocon) faces a regulatory hurdle with a complete response letter from the US Food and Drug Administration (FDA), while Meitheal Pharmaceuticals expands its reach through a strategic licensing agreement with Tonghua Dongbao Pharmaceutical.
Abbott and mAbxience partnership for biosimilars in emerging markets
Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.